Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Genitourinary 2Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 2Pancreatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × naptumomab estafenatox × Genitourinary × Clear all
NCT00420888 2015-07-22

ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma

Active Biotech AB

Phase 2/3 Completed
526 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00056537 2014-08-27

ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

Active Biotech AB

Phase 1 Completed
44 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡